Scleroderma renal crisis

Indian Journal of Medical Sciences

Volumn 61, Issue 2, 2007, Pages 71-72

  Steen, Virginia ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RNA POLYMERASE;

BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MEGADOSE; EDITORIAL; GENETIC DIFFERENCE; HEMOLYTIC ANEMIA; HUMAN; KIDNEY FAILURE; MALIGNANT HYPERTENSION; SCLERODERMA; TREATMENT OUTCOME; URINALYSIS;

EID: 33846686623     PISSN: 00195359     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5359.30346     Document Type: Editorial

References (8)

1. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-3.
2. Helfrich DJ, Banner B, Steen VD, Medsger TA Jr. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989;32:1128-34.
3. Steen VD, Syzd A, Johnson JP, Greenberg A, Medsger TA Jr. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005;32:649-55.
4. Steen VD, Medsger TA Jr, Osial TA Jr, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984;76:779-86.
5. Gupta R, Bammigatti C, Dinda AK, Marwaha V, Gupta S. Prevalence of renal involvement in Indian patients with Systemic Sclerosis. Indian J Med Sci 2007;61:91-6.
6. Okano Y, Steen VD, Medsger TA Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993;119:1005-13.
7. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-9.
8. Denton CP, Black CM. Scleroderma-clinical and pathological advances. Best Pract Res Clin Rheumatol 2004;18:271-90.